EUVIMEDEUVIMED entdecken
Leserbrief

Adjuvant immunotherapy survival: Aligning eligibility, treatment assignment and time zero

Fangrong Jiang iD, Ting Shen iD

Journal of the European Academy of Dermatology and Venereology · 26.10.2026

DOI: 10.1111/jdv.70805 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 26.10.2026. Verfasst von Fangrong Jiang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, The Affiliated Yangming Hospital of Ningbo University, Yuyao, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmunotherapymelanomaobservational studiessurvival analysis

Autor:innen und Institutionen

  • Department of Critical Care Medicine, The Affiliated Yangming Hospital of Ningbo University, Yuyao, China.

ORCID-Profile: Fangrong Jiang, Ting Shen

Zitieren

APA

Jiang, F., & Shen, T. (2026). Adjuvant immunotherapy survival: Aligning eligibility, treatment assignment and time zero. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70805

Vancouver

Jiang F, Shen T. Adjuvant immunotherapy survival: Aligning eligibility, treatment assignment and time zero. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70805

BibTeX
@article{Jiang2026,
  author = {Jiang, Fangrong and Shen, Ting},
  title = {Adjuvant immunotherapy survival: Aligning eligibility, treatment assignment and time zero},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70805}
}
Kostenlos starten →